Loading
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.
Direct links plus the targets, companies, and technologies of this cancer's products.
Shares Receptor conversion: when the receptors change between the primary and a recurrence, DESTINY-Breast06, DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer, HER2-low and HER2-ultralow and the tag subtype-page.
Shares Sacituzumab govitecan, Trastuzumab deruxtecan, Trastuzumab, HER2-positive breast cancer and the tag subtype-page.
Shares HER2 PET, Trastuzumab rezetecan, Trastuzumab deruxtecan, Trastuzumab and the tag subtype-page.
Shares HER2 PET, Trastuzumab rezetecan, Trastuzumab deruxtecan, Trastuzumab and the tag subtype-page.
Shares Trastuzumab, HER2-positive breast cancer, Breast cancer (all types), HR-positive / HER2-negative breast cancer and the tag subtype-page.
Shares HER2 IHC 2+ (equivocal, reflex to ISH), Disitamab vedotin, Trastuzumab deruxtecan, Trastuzumab and the tag subtype-page.
Shares Sacituzumab tirumotecan, Trastuzumab deruxtecan, Trastuzumab and the tag subtype-page.
Shares HER2-low eligibility for trastuzumab deruxtecan, and TROP2 ADCs without a test (triple-negative disease), TROPION-Breast02, HER2-low (IHC 1+ or IHC 2+/ISH-negative), ASCENT and the tag subtype-page.
The same record for scripts and assistants; checked 2026-09-17. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.